Airway remodeling in asthma is a result of persistent inflammation and epithelial damage in response to repetitive injury. Recent studies have identified several important mediators associated with airway remodeling in asthma, including transforming growth factor-β, interleukin (IL)-5, basic fibroblast growth factor, vascular endothelial growth factor, LIGHT, tumor necrosis factor (TNF)-α, thymic stromal lymphopoietin, IL-33, and IL-25. In addition, the epithelium mesenchymal transformation (EMT) induced by environmental factors may play an important role in initiating this process. Diagnostic methods using sputum and blood biomarkers as well as radiological interventions have been developed to distinguish between asthma sub-phenotypes. Human clinical trials have been conducted to evaluate biological therapies that target individual inflammatory cells or mediators including anti IgE, anti IL-5, and anti TNF-α. Furthermore, new drugs such as c-kit/platelet-derived growth factor receptor kinase inhibitors, endothelin-1 receptor antagonists, calcium channel inhibitors, and HMG-CoA reductase inhibitors have been developed to treat asthma-related symptoms. In addition to targeting specific inflammatory cells or mediators, preventing the initiation of EMT may be important for targeted treatment. Interestingly, bronchial thermoplasty reduces smooth muscle mass in patients with severe asthma and improves asthma-specific quality of life, particularly by reducing severe exacerbation and healthcare use. A wide range of different therapeutic approaches has been developed to address the immunological processes of asthma and to treat this complex chronic illness. An important future direction may be to investigate the role of mediators involved in the development of airway remodeling to enhance asthma therapy.
INTRODUCTION
Asthma is a chronic inflammatory disease of the airway that is characterized by the presence of inflammatory cells and structural changes that are referred to as "airway remodeling." Classically, airway remodeling in patients with asthma constitutes subepithelial fibrosis, increased deposition of extracellular matrix protein, goblet cell hyperplasia and mucus gland hypertrophy, smooth muscle hypertrophy and hyperplasia, and epithelial damage [1] [2] [3] . Candidate cells involved in airway remodeling are eosinophils, T-lymphocytes, mast cells, epithelia, macrophages, airway smooth muscle (ASM) cells, and fibroblasts. Immune cells provide mediators that are involved in the process of airway remodeling [4] [5] [6] . Several mediators such as transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), ADAM metallopeptidase domain 33 (ADAM-33), matrix metalloproteinase-9 (MMP-9), and Th2 cytokines (interleukin [IL]-5, IL-13, IL-4, and IL-9) are linked to remodeling [4] [5] [6] . Additional mediators have recently been identified including LIGHT (TNFSF14), tumor necrosis factor (TNF)-α, and basic fibroblast growth factor (bFGF) [7] [8] [9] [10] . Epithelial cells are also important in the initiation of allergic inflammation.
Epithelial injury results in the persistent activation of epithelial mesenchymal transforming unit (EMTU), which promotes airway remodeling, leading to persistent asthma [10, 11] . Epithelial injury increases the expression of thymic stromal lymphopoietin (TSLP), IL-33, and IL-25, which induce Th2 memory cell expansion and cytokine secretion [12] . Clinicians seek additional options other than the currently available conventional treatments to improve the condition of patients with severe asthma and to spare systemic corticosteroid administration. This review presents recent advances in the mechanism, diagnosis, and treatment of asthma, focusing on the use of mediators for airway remodeling therapy, as well as procedures that assess asthma severity. Animal research and human studies have enabled clinicians to better evaluate the extent of airway remodeling and to design specific treatment strategies appropriate for each patient.
MECHANISMS OF AIRWAY REMODELING: A LINK BETWEEN CELLS AND MEDIA-TORS
Animal studies using models of airway remodeling and human studies both support the finding that immune or inflammatory cells and mediators are important in the pathogenesis of airway remodeling (Fig. 1 ). For example, recent studies have demonstrated that environmental factors cause a defect in the epithelia, inducing an innate immune response by activating dendritic cells and Th2 memory cells to release mediators linked to remodeling [13] .
In addition, eosinophils are immune cells that express TGF-β, which acts as a key mediator during airway remodeling. Studies using anti IL-5 antibody to deplete eosinophils have reported a link between eosinophilic depletion and decreased TGF-β expression. Other cell types such as bronchial epithelial cells and macrophages may also express TGF-β in the lung. It is essential to understand the link between cells and mediators during remodeling to enhance current biological therapies for asthma.
Eosinophil related cytokines: IL-5,CCR-3, Siglec-8(F)
Allergen-induced murine models of airway remodeling have highlighted the importance of eosinophils during airway remodeling. IL-5 transgenic mice exhibit an increase in eosinophils in the lung, accumulation of peribronchial eosinophils, goblet cell hyperplasia, epithelial hypertrophy, and focal collagen deposition. They also show airway hyper-responsiveness (AHR) to methacholine in the absence of an aerosolized antigen challenge [4] . IL-5, chemokine receptor (CCR)-3, and siglec-8(F) are critical molecules associated with eosinophilic trafficking in target organs.
IL-5
IL-5 is a key cytokine that regulates the proliferation and differentiation of eosinophils, as well as the trafficking of eosinophils from the bone marrow to the lung [14, 15] . A remarkable reduction in TGF-β-expressing eosinophils occurs in the remodeled airways of IL-5-deficient mice. Anti IL-5 treatment significantly reduces levels of bronchoalveolar lavage (BAL) eosinophils and remodeling, as assessed by reduced deposition of the extracellular matrix-associated remodeling proteins procollagen and tenascin [16] . Furthermore, the anti IL-5 antibody mepolizumab decreases airway thickness and wall area in patients with refractory asthma [17] . Several anti IL-5 antibodies including mepolizumab, reslizumab, and enralizumab (MEDI563) are now in clinical trials. However, blocking IL-5 alone only reduces 50-60% of tissue eosinophils; therefore, additional blocking of eosinophil trafficking may be required to completely block eosinophils.
CCR-3
CCR-3 is a chemokine receptor expressed by eosinophils that mediates chemotaxis in response to chemokines including eotaxin and RANTES. CCR-3-deficient mice and eotaxin-deficient mice show decreased levels of airway eosinophilia and mucus production [6] . Reduced subepithelial fibrosis and goblet cell hyperplasia are observed in a mouse model of airway remodeling subjected to lowmolecular-weight CCR-3 antagonists [18] . A recent study administered a CCR-3 receptor antagonist (Ki19003) to an ovalbumin (OVA)-induced asthma model and found that Ki19003 inhibits airway eosinophilic inflammation and peribonchial fibrosis, and increases levels of TGF-β in BAL [19] . An oral CCR-3 antagonist (GW766944) is now on clinical trial (ClinicalTrials.gov NCT01160224).
Siglec-8
Siglec-8 is highly expressed on human eosinophils and is a candidate molecule that may be targeted to alleviate eosinophilic inflammation. The siglec-8 receptor crosslinks with eosinophils to induce an apoptotic signal.
Mouse siglec-F shares many properties with human siglec-8, including predominant expression on eosinophils and unique ligand specificity. Thus, mouse siglec-F has provided insight into the potential role of siglec-8 in human allergic disease [20, 21] . A recent study used a chronic OVA-challenged murine model to demonstrate that siglec-F plays a role in airway remodeling by modulating eosinophilic apoptosis in lung and bone marrow; furthermore, treatments using anti siglec-F antibody significantly reduced the number of peribronchial TGF-β-expressing eosinophils and the level of peribronchial fibrosis [22] . A significant increase in mucus production, peribronchial fibrosis, and smooth muscle thickness occurs in chronic OVA-challenged mice deficient in siglec-F; IL-4 or IL-13 significantly increase the level of siglec-F ligand expression in bronchial epithelium. Thus, human siglec-8 may be an additional target to modulate eosinophil recruiting during human airway remodeling [23] .
LIGHT (TNFSF14; homologous to lymphotoxin): lymphocytes
The TNF superfamily (TNFSFs) consists of many membrane-bound and soluble proteins that act as key mediators of asthmatic inflammation such as the OX40 ligand (TNFSF4) and TNF itself. The TNF family ligand LIGHT (TNFSF14) is expressed on B and T cells but not on macrophages and granulocytes [7] . LIGHT binds the herpesvirus entry mediator (TNFRSF14). It also acts as a ligand for membrane lymphotoxin (LTαβ). Lymphotoxin β receptor (LTβR) is strongly expressed on macrophages [7] . A recent study reported an increase in soluble LIGHT in the sputum of patients with asthma, highlighting the role of LIGHT (TNFSF14) in asthma. LIGHT levels in BAL fluid are higher in patients with pulmonary fibrosis [24] . Pharmacological inhibition of LIGHT using the IgG Fc domain and LTβR reduces lung fibrosis, smooth a Bronchoscopic procedure which delivers thermal energy to the airway wall to reduce excess airway smooth muscle. muscle hyperplasia, and AHR in mouse models of chronic asthma. LIGHT-deficient mice also show a similar disruption of fibrosis and smooth muscle hyperplasia, whereas exogenous administration of LIGHT induces fibrosis and smooth muscle hyperplasia. Thus, LIGHT may be a potential target to prevent and/or treat airway remodeling [24] .
Mediators from multiple cell types: TGF-β, bFGF, VEGF, TNF-α, MMPs
TGF-β
TGF-β is a profibrotic cytokine, another key airway remodeling mediator in asthma [25] . TGF-β is produced by several cell types, including epithelial cells, eosinophils, macrophages, and fibroblasts. It is involved in epithelial changes, subepithelial fibrosis, ASM remodeling, microvascular changes, and increased mucus production. [26, 27] . Furthermore, TGF-β decreases the production of enzymes that degrade the extracellular matrix (collagenase) and increases the production of proteins that inhibit enzymes that degrade the extracellular matrix (tissue inhibitor of metalloprotease, TIMP) [28] .
Smad3 is a TGF-β signaling molecule. Smad3-deficient mice chronically challenged with allergen show reduced numbers of peribronchial myofibroblasts and decreased peribronchial fibrosis [29] . Neutralizing TGF-β expression either by blocking TGF-β signaling in the Smad-3 pathway or administering anti activin-A significantly reduces peribronchial fibrosis, ASM proliferation, and mucus production [30] . Increased levels of TGF-β have been reported in BAL and biopsy specimens of patients with asthma [31, 32] . TGF-β expression correlates with the degree of subepithelial fibrosis. Levels of TGF-β increase significantly in patients with severe asthma and prominent airway eosinophilic inflammation. TGF-β levels in the lungs of patients with asthma decrease by depleting eosinophils through anti IL-5 antibody treatment. Surprisingly, very few preclinical experiments using TGF-β inhibitors have been published [33] . Currently, a monoclonal anti TGF-β antibody (GC1008) is being tested in a phase I study to treat idiopathic pulmonary fibrosis (NCT00125385). bFGF bFGF is a cytokine that is mitogenic to fibroblasts and smooth muscle [34] [35] [36] , and has proangiogenic properties related to angiogenesis during airway remodeling. Cellular sources of bFGF include macrophages, endothelial cells, mast cells, epithelial cells, and fibroblasts [37] . bFGF binds to 1-4 high-affinity FGF receptors [38] . A study using chronic OVA-induced airway remodeling demonstrated that bFGF is expressed by peribronchial macrophages and epithelium. Furthermore, bFGF and TGF-β1 are coexpressed on peribronchial macrophages, implying an association between these molecules during airway remodeling. The synergistic effects of bFGF and TGF-β1 have also been found in other cell types [39] . Mast cell-derived activin A, an activator of Smad2/3/4 and a potent inducer of human ASM cell proliferation, could be the main TGF-β superfamily member that synergizes with bFGF to induce ASM hyperplasia [40] . Interestingly, bFGF administration reduces airway inflammation and AHR in an acute OVAchallenged murine model of asthma [41] . Clinical studies have found an increase in the presence of bFGF immunoreactive cells and levels of bFGF protein in the sputum and BAL fluid of patients with asthma compared to nonasthmatic controls [42, 43] . Further studies are needed to clarify the role of bFGF during airway remodeling.
VEGF
VEGF is a critical multifunctional angiogenic regulator that stimulates epithelial cell proliferation, blood vessel formation, and endothelial cell survival [44] . VEGF has been postulated to contribute to asthmatic tissue edema through its effects on vascular permeability [45, 46] . Lungtargeted VEGF165 transgenic mice have an asthma-like phenotype that includes not only vascular remodeling but also inflammation, edema, mucus metaplasia, myocyte hyperplasia, and AHR [47] . Recent studies that investigated the mechanism of VEGF in a murine model of asthma have shown that nitric oxide is an important mediator of the extravascular VEGF remodeling effects [48] . VEGF is elevated in induced sputum, BAL fluid, and bronchial biopsies of patients with asthma [49] . A comparative study of two angiogenic factors, VEGF and angiogenin, dem-http://www.kjim.or.kr onstrated that children with asthma have significantly higher levels of VEGF and angiogenin than non-asthmatic children, and that the increased levels of VEGF and angiogenin are correlated to asthma severity [50] . In addition, sputum VEGF levels in smoking patients with asthma are significantly lower than those in nonsmoking patients with asthma but remain higher than those in control subjects [51] . Based on these findings, VEGF may be involved in vascular and airway remodeling in patients with asthma.
TNF-α
TNF-α is a pro-inflammatory cytokine that increases in the airways of patients with asthma. TNF was initially believed to be produced primarily by macrophages but has been shown to be expressed by a broad range of cell types including mast cells and eosinophils [52, 53] . Allergenchallenged TNFp55/p75 receptor-deficient mice have significantly reduced levels of peribronchial eosinophils and fibrosis [8] . Increased TNF-α levels in BAL are associated with increased levels of remodeling in patients with asthma.
Inhibiting TNF-α reduces asthma exacerbation, further suggesting that TNF-α may be related to airway remodeling. A study using etanercept, a fusion protein consisting of the type II TNF receptor that binds both TNF-α and β, found that patients with refractory asthma have increased expression of membrane-bound TNF-α, TNF-α receptor 1, and TNF-α converting enzyme [55] . These findings collectively suggest that TNF-α may be involved in asthma airway remodeling through eosinophils and mast cells.
MMP-9 and ADAM-33
MMP-9 belongs to a family of extracellular proteases that are responsible for degrading the extracellular matrix during tissue remodeling. An example of MMP-9 activity is the broad-spectrum MMPI inhibitor R 94128, which reduces the development of allergic airway inflammation [56] . An MMP-9-deficient murine asthma model showed reduced peribronchial fibrosis and total lung collagen compared to wild-type mice, yet no difference was detected in mucus expression, smooth muscle thickness, or airway responsiveness [57] . Moreover, human studies have shown that levels of MMP-9 (gelatinase B) increase significantly in BAL fluid, blood, and sputum of patients with allergic asthma [58] . Thus, therapies targeting MMP-9 may not only decrease airway inflammation but also reduce the levels of peribronchial fibrosis during airway remodeling.
ADAM-33 is a disintegrin and a metalloprotease expressed in patients with asthma [59] . Allergen-challenged ADAM-33-deficient mice show no significant differences in airway hyper-reactivity, IgE production, mucus metaplasia, or airway inflammation compared to wild type mice [1] . However, ADAM-33 mRNA expression is significantly enhanced in the lung tissue of OVA-challenged mice [60] . A genetic polymorphism in ADAM-33 is a novel asthma-associated gene, which results in an accelerated decline in lung function over time. Furthermore, ADAM-33 mRNA expression is higher in patients with severe asthma than in patients with mild asthma or without asthma [61] .
ADAM-33 may be a key molecule that contributes to ASM and vascular remodeling.
Epithelium related mediators: TSLP, IL-25, IL-33
The epithelium plays an important role initiating allergic inflammation. Epithelial injury results in persistent activation of the EMTU [11] , an attenuated fibroblast sheath that is in contact with bronchial epithelium and coordinates airway remodeling following epithelial injury. Epithelial injury caused by viruses, fungus, double-stranded RNA, and protease allergens increase TSLP, IL-33, and IL-25 expression, which induces Th2 memory cell expansion and Th2 cytokine secretion [62] .
TSLP
TSLP, a distant paralog of IL-7, is a type I cytokine and a member of the IL-2 cytokine family. TSLP is expressed by the epithelium, keratinocytes, macrophages, neutrophils, and mast cells. A recent study demonstrated that TNF-α induces TSLP in human ASM as well [63] . Transgenic mice that overexpress TSLP show increased levels of allergic inflammation similar to that in human asthma. Allergenchallenged mice deficient in TSLP-receptor knockdown exhibit suppressed airway inflammation [64] . Zhang et al. [65] demonstrated that a soluble TSLP antagonist, TSLPRimmunoglobulin, reduces the severity of allergic disease.
House dust mite protease upregulates epidermal growth factor receptor-dependent protease activated receptor-2 and thymus and activates activation-regulated chemokine and TSLP, which results in epithelium mesenchymal transformation (EMT) and, ultimately, airway remodeling [66, 67] . In humans, increased levels of TSLP have been found in airway epithelium and other inflammatory cells of patients suffering from asthma and chronic obstructive pulmonary disorder [68, 69] . TSLP expression in the airways of patients with asthma is correlated with expression of Th2 cytokines and disease severity [70] . Thus, TSLP may play an important role in asthma airway remodeling by inducing EMT.
IL-25 (IL-17E)
IL-25 (IL-17E) is a member of the IL-17 cytokine family that evokes TH2 cell-mediated immunity to parasitic infections [71] . Its upregulation induces a robust expansion of TH2 memory cells by TSLP-activated dendritic cells [12] .
IL-25 is not only expressed by lung epithelial cells but also by mast cells, eosinophils, and basophils and is considered part of the innate immune response [72, 73] . Moreover, IL-25R is also found on eosinophils, monocytes, ASM cells, and fibroblasts [12] ; the expression of IL-25R on these inflammatory and structural cells suggests that it may be involved in airway remodeling. Transgenic overexpression of IL-25 leads to mucus production and airway infiltration by macrophages and eosinophils, whereas IL-25 blockade reduces airway inflammation and TH2 cytokine production in a murine allergen-induced asthma model [72] . 
IL-33
IL-33 is a member of the IL-1 family, associated with promoting a systemic Th2 response [76] . in the lung [80, 81] . IL-33 transgenic mice spontaneously develop eosinophilic inflammation [82] . Administering the anti IL-33 also abrogates Th2 cytokine secretion and eosinophilic recruitment [83] . IL-33-deficient mice are resistant to allergen-induced AHR [84] . The subcutaneous administration of IL-33 results in ST2-dependent recruitment of eosinophils, CD3+ lymphocytes, F4/80 macrophages, increased IL-13 mRNA, and the development of cutaneous fibrosis [85] . In human studies, IL-33 expression in epithelial cells increases in patients with asthma compared to healthy individuals and increases more dramatically in patients with severe asthma [86] . IL-33 and ST2 gene polymorphisms have been linked to asthma [87] .
Higher IL-33 expression is also found in other allergic diseases, including allergic conjunctivitis, rhinitis, and atopic dermatitis. It is difficult to make a direct correlation between IL-33 and airway remodeling. However, previous findings suggest that IL-33 may be an important factor during airway remodeling. (Fig. 2) .
ASSESSMENT OF AIRWAY REMODELING
Non
Non-invasive methods
PFTs using methacholine or exercise provocation have been a traditional diagnostic tool for assessing AHR in patients with asthma. Studies have been conducted to evaluate the efficacy of PFT as an airway-remodeling assessment method. A longitudinal population study of asthma from childhood to adulthood demonstrated that a low postbronchodilator ratio of FEV1 to vital capacity is useful as an airway remodeling marker, which, in turn, was associated with an accelerated decline in lung function and reversibility [88] . Many studies have shown that computed tomography scans may be useful for assessing airway remodeling by measuring bronchial wall thickness [89] . A recent retrospective quantitative analysis of HRCT scans in 99 patients with severe asthma versus 16 healthy controls demonstrated that the right upper apical segmental bronchus (RB1) wall area (WA) % increases in patients with severe asthma, whereas the ratio of lumen area to body surface area decreases. Moreover, increased WA% of RB1 in patients with severe asthma was associated with impaired lung function and neutrophilic inflammation in a sputum study [90] . Quantitative densitometry of computed tomography (CT) images serves as an additional tool for non-invasively studying airway remodeling in patients with asthma [91] . Hyperpolarized gas MRIs of patients with asthma commonly exhibit ventilation defects; the size and the extent of the ventilation defects are correlated with the severity of regional airway closure and narrowing. A recent study demonstrated that the ventilation defects on MRI images of patients with moderate to severe asthma are significantly greater than those of patients with mild asthma [92] . Another study using hyperpolarized helium-3 MRI found a moderate correlation between the number of ventilation defects and predicted FEV1%. However, no significant correlation was found between the total number of ventilation defects and whole lung inflammation markers in BAL analysis [93] . CT and MRI have been and will continue to be instrumental for assessing airway remodeling to provide treatments for asthma in the future.
Sputum induction is another useful tool that assesses the degree of inflammation by measuring the levels of mediators in patients with asthma. Because the levels of lung inflammation correlate with airway remodeling severity, the absolute numbers of inflammatory cells, including eosinophils, neutrophils, and macrophages, are used to help assess the development of airway remodeling. In a study that examined osteopontin in patients with severe refractory asthma, the levels of sputum supernatant cysteinyl leukotrienes IL-13, TGF-β1, and eosinophilic cationic Figure 2 . Evaluation and treatment approach during asthmatic airway remodeling. Non-invasive methods such as the pulmonary function test (PFT), high-resolution computed tomography (HRCT), and magnetic resonance imaging (MRI) are utilized first to assess the degree of airway remodeling. Invasive methods such as sputum induction for inflammatory cells and biological markers, blood eosinophils and IgE, bronchoscopic biopsy or bronchoalveolar lavage, and endobronchial ultrasonography may be applied for a more detailed determination of airway remodeling. Additional treatment including biological therapy and bronchial thermoplasty can then be used as a more mechanical approach to treatment based on asthma subtype. CT, computed tomography; CS, corticosteroid; LT, leukotriene; IL, interleukin; TNF, tumor necrosis factor. a FDA-approved for patients with severe asthma. protein (ECP) were higher in patients with severe asthma than in healthy subjects [94] . Another study, which focused on persistent remodeling and eosinophil activation,
showed that histamine and ECP levels from patients with asthma in complete remission are significantly lower than those in patients who continue to suffer from severe asthma [95] . A study of the effects of formoterol-budesonide on airway remodeling in patients with asthma demonstrated a significant decrease in the levels of MMP-9, TIMP-1, and TGF-β1 after treatment [96] .
Blood eosinophil number, serum IgE level, and other biomarkers may also indicate the level of airway remodeling. A study of occupational asthma biomarkers demonstrated that serum VEGF, MMP-9, and other markers could be measured in three diisocyanate-induced patients with occupational asthma (TDI-OA) and found that serum MMP-9 level is elevated in patients with TDI-OA compared to that in healthy control subjects [97] . Thus, measuring sputum and serum eosinophil biomarker levels could be useful for assessing the degree of asthmatic airway remodeling.
Invasive methods
EBUS has been used to assess bronchial wall remodeling in patients with asthma [98] . This method correlates asthma severity parameters to bronchial wall layers. 
RECENT TREATMENT STRATEGIES FOR AIRWAY REMODELING
Conventional treatments do not adequately control some severe cases of asthma. This has been a major clinical challenge, which is becoming an important healthcare issue. In the last decade, this dilemma has fostered the development of several biological and pharmacological agents to provide possible mechanical treatments for ASM.
Phenotyping each patient will be very important to specifically tailor treatment for patients with severe asthma.
Biologic therapy (Table 1)
Monoclonal antibodies against IgE or cytokines includ- 
Anti IL-5 antibody: mepolizumab, reslizumab, enralizumab (MEDI-563)
Mepolizumab is a high-affinity, anti IL-5, humanized
IgG1 monoclonal antibody that blocks IL-5 binding to eosinophils. Based on animal studies, blocking IL-5 may be related to improving airway remodeling via eosinophil regulation of TGF-β during the remodeling process. This antibody was initially evaluated in a group of patients with mild to moderate asthma and was demonstrated to significantly reduce blood eosinophils but did not result in a significant improvement in clinical parameters [16] . A study on 61 patients found that mepolizumab decreases blood and sputum eosinophil levels, prevents further asthma exacerbation, and improves asthma-related quality-of-life scores [104] . For example, a clinical trial in which mepolizumab was given to patients with asthma for 6 months showed reduced exacerbation frequency and steroid requirements [104, 105] . Gruenberg and Busse's study [106] suggested that patients who are being treated with steroid therapy and continue to have persistent sputum eosinophilia may benefit from an agent that can specifically target and reduce eosinophils. Clinical trials with other anti IL-5 antibodies, including reslizumab and enralizumab, are currently in progress.
Anti TNF-α: etanercept, infliximab, and golimumab
Etanercept (a soluble form of the recombinant TNF-α human receptor) has been used to improve FEV1 scores and the quality of life of patients with severe refractory asthma [55] . However, a recent phase II clinical study of 
IL-4 and IL-13 targeted drugs: anti IL4R-α antibody (AMG-317), a recombinant human IL-4 variant (pitrakinra)
Receptors New pharmacologic targets for airway remodeling in asthma (Table 2 
c-kit/PDGF receptor tyrosine kinase inhibitor: mastinib
The c-kit/PDGF receptor tyrosine kinase inhibitor imatinib mesylate decreases peribronchial collagen deposition and ASM thickening in a murine model of asthma [115] .
Based on these animal study results, a clinical study evaluated the effects of mastinib in a small group of patients with severe persistent asthma [116] . Mastinib lowered the asthma control questionnaire score and reduced the frequency of asthma exacerbations. However, no significant improvement in lung function was observed in the treatment group. Further studies on a larger number of patients are needed to determine its efficacy.
ET-1 receptor antagonist: sitaxentan
ET-1 induces bronchoconstriction, mediates eosinophil recruitment during allergic inflammation, and contributes to airway remodeling by inducing fibroblast and smooth muscle cell differentiation and proliferation [117] . Increased ET-1 expression on ASM areas is strongly correlated with airway obstruction (measured by FEV1) in patients with asthma [118] . Another study reported that an ET-1 receptor polymorphism is strongly associated with the degree of airway obstruction in a population of patients with asthma [119] . These data suggest that inhibiting the ET-1 pathway could be a potential therapeutic option in patients with steroid-refractory asthma or an irreversible airway obstruction. The ET-1 receptor antagonist sitaxentan is now in clinical trials on patients with severe persistent asthma.
Calcium channel inhibitor: methoxyverapamil (gallopamil)
Airway remodeling mainly involves increased ASM mass, which is related to increased smooth muscle cell proliferation. Calcium influx in smooth muscle cells activates calcium-calmodulin kinase IV (CamK-IV). CamK-IV then enhances mitochondrial biogenesis through subsequent activation of various transcription factors. In vitro studies show that ASM cell proliferation in patients with severe asthma is mainly mitochondria-dependent, whereas that of controls is virtually mitochondria-independent [120] . Gallopamil administration induces a reduction in mitochondrial mass and subsequent ASM cell proliferation and is now in clinical trials on patients with severe persistent asthma.
HMG-CoA reductase inhibitor: statins-simbastatin, atorvastatin, and lovastatin
HMG-CoA reductase inhibitors (statins) are well-known cholesterol-lowering agents. Interestingly, they also have pleiotropic effects, which include inhibiting ASM cell proliferation and promoting ASM cell apoptosis. Despite promising in vitro results, two clinical trials have demonstrated that neither simbastatin [121] nor atrovastatin [122] improve inflammatory outcomes and lung function in patients with allergic asthma. Lovastatin administration in patients with severe persistent asthma is now being evaluated for its effects on airway remodeling in clinical trials.
Bronchial thermoplasty (BT, Table 3)
BT is a bronchoscopic procedure for patients with severe persistent asthma; it delivers thermal energy to the airway wall to reduce excess ASM. Preclinical studies have shown that BT results in a reduction in ASM and AHR in an animal model [123, 124] . Initially, a clinical study with 16 patients confirmed that BT increases the number of mild to moderate asthma symptom-free days and the peak expiratory flow rate (PEF) at 3 months, in addition to reducing AHR for 2 years [125] . In a study of patients with moderate to severe asthma, BT significantly alleviated mild exacerbations, reduced the use of reliever medicine, and improved morning PEF, resulting in improved asthma-related questionnaires scores [126] . The recently conducted Asthma Intervention Research (AIR) study demonstrated that BT improves asthma-specific quality of life with a reduction in severe exacerbation and healthcare use during the post-treatment period in patients with severe asthma [127, 128] . A long-term (5-year) safety study of BT (AIR trial) reported that clinical complications did not increase over time, based on the rate of adverse respiratory events. It also determined that lung function (FVC and FEV1) had not deteriorated over a 5-year period post-BT in patients with moderate to severe asthma. These findings suggest that BT treatment is a safe procedure with effects that last at least 5 years [129] . BT was approved by the FDA in April 2010 for patients with severe asthma.
CONCLUSION
Asthma is a complex disease derived from the interaction between inhaled environmental agents and the airway. This review focused on recent advances in mechanisms, diagnosis, and treatment of airway remodeling in patients with asthma during the last decade. Numerous animal studies and clinical trials using biological therapy, drugs, and mechanical disruption of airway remodeling have been conducted. Acquiring detailed information on asthma subtypes for individual patients will help develop more specific and effective target treatments for severe asthma. Anti IL-5 and anti IgE therapy effectively reduce asthma exacerbation in patients with severe asthma. 
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